Both trials met their primary endpoints, demonstrating treatment with RelabotulinumtoxinA resulted in a statistically significant improvement in frown lines and crow’s feet.1,2
Results reinforce the rapid onset of action of RelabotulinumtoxinA, with some patients reporting improvement as early as day one in both trials.1,2
Results also underscore the durability of RelabotulinumtoxinA with at least a third of patients rating their frown lines as ‘improved’ or better through to month 12 in one study.2
Treatment was well tolerated and all treatment-related adverse events were reported as non-serious.1,2
ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet). Both studies met their primary endpoints, demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, significantly improves both frown lines and crow’s feet, with a rapid onset of action as early as day one and long duration.1,2
|
“These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of RelabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
